Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | F3Y25 | — |
pediatric havrix vaccine administered to a 57 years old adult; pediatric havrix vaccine administered to a 57 years old adult; Expired Dose Administered; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of adult use of a child product in a 57-year-old female patient who received HAV (Havrix pediatric) (batch number F3Y25, expiry date 15-FEB-2025) for prophylaxis. On 18-MAR-2025, the patient received Havrix pediatric. On 18-MAR-2025, an unknown time after receiving Havrix pediatric, the patient experienced adult use of a child product (Verbatim: pediatric havrix vaccine administered to a 57 years old adult), underdose (Verbatim: pediatric havrix vaccine administered to a 57 years old adult) and expired vaccine used (Verbatim: Expired Dose Administered). The outcome of the adult use of a child product, underdose and expired vaccine used were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 18-MAR-2025 Pharmacist reported that a pediatric havrix vaccine was administered to a 57 years old adult which led to adult use of a child product and underdose. The vaccine had actually expired on 15 February 2025 which led to expired vaccine used. Over a month ago so, it was still in the stock. The reporter wanted to know if there was a recommendation to revaccinate with an adult dose The reporter was not sure which number of dose it was and she did not know the date of birth of the patient.